Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accumulated Expenses (2016 - 2021)

Fortress Biotech has reported Accumulated Expenses over the past 9 years, most recently at $82.9 million for Q3 2021.

  • Quarterly results put Accumulated Expenses at $82.9 million for Q3 2021, up 360139.13% from a year ago — trailing twelve months through Sep 2021 was $82.9 million (up 360139.13% YoY), and the annual figure for FY2020 was $45.4 million, up 78.7%.
  • Accumulated Expenses for Q3 2021 was $82.9 million at Fortress Biotech, up from $59.9 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for FBIO hit a ceiling of $82.9 million in Q3 2021 and a floor of $23000.0 in Q3 2020.
  • Median Accumulated Expenses over the past 5 years was $17.5 million (2018), compared with a mean of $22.3 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 97.79% in 2020 and later soared 360139.13% in 2021.
  • Fortress Biotech's Accumulated Expenses stood at $17.6 million in 2017, then fell by 7.21% to $16.4 million in 2018, then soared by 55.25% to $25.4 million in 2019, then surged by 78.7% to $45.4 million in 2020, then surged by 82.54% to $82.9 million in 2021.
  • The last three reported values for Accumulated Expenses were $82.9 million (Q3 2021), $59.9 million (Q2 2021), and $27.8 million (Q1 2021) per Business Quant data.